<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564405</url>
  </required_header>
  <id_info>
    <org_study_id>UNI-DEB-Pilot</org_study_id>
    <nct_id>NCT03564405</nct_id>
  </id_info>
  <brief_title>Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>A Open, Single-arm, Uncontrolled, Single Center, Pilot Study to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable&#xD;
      Hepatocellular Carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2016</start_date>
  <completion_date type="Actual">May 17, 2017</completion_date>
  <primary_completion_date type="Actual">March 7, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>4 weeks after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>UNI-DEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UNI-DEB</intervention_name>
    <description>Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient</description>
    <arm_group_label>UNI-DEB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 19 years&#xD;
&#xD;
          -  Diagnosis of HCC&#xD;
&#xD;
          -  Unresectable asymtomatic uninodular or multinodular tumor.&#xD;
&#xD;
          -  Subject who maintain clinically normal hepatopetal flow without main portal vein&#xD;
             closure&#xD;
&#xD;
          -  At least one measurable target lesion by CT or MRI which 10 mm or more.&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          -  Child-Pugh class A or B&#xD;
&#xD;
          -  Life expectancy of at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Another primary tumour, with the exception of conventional basal cell carcinoma or&#xD;
             superficial bladder neoplasia&#xD;
&#xD;
          -  Hepatic resection, liver transplantation or Percutaneous local treatment&#xD;
&#xD;
          -  Previously received HCC related medical procedure&#xD;
&#xD;
          -  Previously treated with anthracyclines&#xD;
&#xD;
          -  Only measurable disease is within an area of the liver previously subjected to&#xD;
             radiotherapy.&#xD;
&#xD;
          -  Child Pugh C&#xD;
&#xD;
          -  Active gastrointestinal bleeding within 6 months from screening.&#xD;
&#xD;
          -  Total bilirubin &gt; 3mg/dL&#xD;
&#xD;
          -  WBC &lt; 3,000cells/mm3&#xD;
&#xD;
          -  ANC &lt; 1,500cells/mm3&#xD;
&#xD;
          -  Platelet &lt; 50,000mm3&#xD;
&#xD;
          -  Serum creatinine &gt; 2mg/dL&#xD;
&#xD;
          -  INR &gt; 1.4&#xD;
&#xD;
          -  ALT and AST &gt; 5 times UNL&#xD;
&#xD;
          -  Diffuse HCC defined as &gt;50% tumor involvement of the whole liver.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University Seoul St. Mary Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

